KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Receivables for 15 consecutive years, with $189.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 29.8% to $189.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $189.6 million, a 29.8% increase, with the full-year FY2025 number at $189.6 million, up 29.8% from a year prior.
  • Receivables was $189.6 million for Q4 2025 at Supernus Pharmaceuticals, up from $177.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $189.6 million in Q4 2025 to a low of $127.1 million in Q1 2021.
  • A 5-year average of $149.8 million and a median of $145.9 million in 2024 define the central range for Receivables.
  • Peak YoY movement for Receivables: decreased 13.61% in 2023, then grew 29.8% in 2025.
  • Supernus Pharmaceuticals' Receivables stood at $148.9 million in 2021, then increased by 11.12% to $165.5 million in 2022, then decreased by 12.9% to $144.2 million in 2023, then grew by 1.33% to $146.1 million in 2024, then increased by 29.8% to $189.6 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Receivables are $189.6 million (Q4 2025), $177.6 million (Q3 2025), and $146.2 million (Q2 2025).